Novartis back in Huntington’s with $1B licensing deal with PTC
Novartis has signed a licensing deal with PTC Therapeutics for an experimental Huntington’s disease treatment, with an upfront payment of $1 billion. The agreement also includes the potential for another $1.9 billion in payments based on hitting development, regulatory, and commercial milestones. Novartis CEO Vas Narasimhan stated that this deal aims to strengthen their neuroscience…